We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Global Hematology Diagnostics Market Driven by Rising Prevalence of Blood Disorders

By LabMedica International staff writers
Posted on 06 Sep 2022
Print article
Image: The global hematology diagnostics market is expected to surpass USD 5.5 billion by 2026 (Photo courtesy of Pexels)
Image: The global hematology diagnostics market is expected to surpass USD 5.5 billion by 2026 (Photo courtesy of Pexels)

Hematology is defined as the diagnostic classification of cells present in the blood and resulting identification of diseases of the blood-forming organs and diseases of the blood. It includes the calculation of WBC, RBC, and platelets. The analysis of hematologic disorders is related to disease monitoring, prognosis, diagnosis, and screening. Hematology testing devices have come a long way from disease detection and monitoring to counting and characterizing blood cells. The concept of automation has extended to detect small cell populations in order to diagnose rare blood conditions, which requires less labor, rapid result, and easy-to-use analyzers. Current technologies include automation of hematology analyzer, electrical impedance, flow cytometry, and fluorescent flow. The combination of these technologies has increased the yield and productivity of test results.

The global hematology diagnostics market was valued at approximately USD 3.5 billion in 2017 and is anticipated to expand at a CAGR of more than 5% from 2018 to 2026 to reach about USD 5.5 billion by 2026. The market is expected to be driven by a rise in the prevalence of blood disorders, technological advancements and introduction of new, technically-advanced fully automated hematology analyzers, significant demand for laboratory automation, and increase in consolidation among market players and diagnostic laboratories. These are the latest findings of Transparency Market Research Inc. (Wilmington, DE, USA), a global market research company.

The rapid expansion of the global hematology diagnostics market can be attributed primarily to the increasing prevalence of blood disorders. A rise in awareness about these disorders among health care professionals and patients is expected to drive higher demand for hematology diagnostics. Test volume, i.e. number of tests performed, is expected to increase owing to technological advances in disease diagnosis, and rise in demand for preventive diagnosis and treatment monitoring. This is also fueling the demand for hematology analyzers with high throughput. The technological revolution in hematology testing is expected to propel market growth during the forecast period.

Based on product type, the hematology consumables segment is expected to maintain its dominance of the hematology diagnostics market due to rising awareness of blood disorders among health care professionals and patients that is likely to drive higher demand for hematology analyzers and consumables. Within the hematology consumables segment, reagents was the leading sub-segment in 2017 and is anticipated to maintain its dominance during the forecast period. The expansion of the hematology consumables segment is likely to fuel the growth of the global hematology diagnostics market during the forecast period. However, the hematology instruments segment is likely to lose market share during the forecast period. Within the hematology instruments segment, hematology analyzers was the leading sub-segment in 2017 and is likely to maintain its dominance during the forecast period.

Geographically, North America held a major share of the global hematology diagnostics market in 2017 due to technological advancements in instruments, ease of usage, and favorable reimbursement scenario in the region. The U.S. and Canada are rapidly advancing the frontiers of research and technological development as well as setting stringent standards for analysis of blood products quality. This, in turn, is likely to propel the growth of the North American hematology diagnostics market during the forecast period. Asia Pacific is witnessing rapid development. High per capita income has increased utilization of diagnostic and therapy products in the region. The rapid expansion of the hematology diagnostics market in Asia Pacific can be attributed to numerous government initiatives undertaken to improve the health care infrastructure. The development of health care infrastructure, rise in population, boom in the biotechnology industry, and increasing burden of diseases requiring diagnostic tests are driving the growth of the hematology diagnostics market in Latin America and Middle East & Africa.

Related Links:
Transparency Market Research Inc. 

Gold Supplier
STI Real-Time PCR Test
Neisseria Gonorrhoeae/Chlamydia Trachomatis/U.urealyticum Real-Time PCR Kit
Radiotherapy Toxicity Measurement Assay
Radiotherapy Toxicity Measurement Assay
Dengue IgG Test
Chorus Dengue IgG
cTnl ELISA Test Kit

Print article


Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: Researchers have identified the origin of subset of autoantibodies that worsen lupus (Photo courtesy of Pexels)

Lupus Biomarker Testing Could Help Identify Patients That Need Early and Aggressive Treatment

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body's antibodies, which usually protect against infections, attack healthy cells and proteins. These autoantibodies can... Read more


view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more


view channel
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research... Read more


view channel
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses... Read more


view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.